January 26, 2018 - 9:00am

Health and Human Services Commission, John H. Winters Human Services Complex, Public Hearing Room
701 West 51st St.
Austin, TX 78751

Webcasting Available

  1. Call to order
  2. Approval of minutes from November 3, 2017 (Vote required)
  3. Old business: Report on Health and Human Services Commission decisions on acceptance of the Drug Utilization Review (DUR) Board recommendations from the November 3, 2017, meeting
  4. New business:

    Public comment on drug classes to be reviewed and clinical drug reviews to be reviewed for the Medicaid Preferred Drug List (PDL):

    1. Acne agents, oral
    2. Acne agents, topical
    3. Analgesics, narcotic long
    4. Analgesics, narcotic short
    5. Angiotensin modulator combinations
    6. Angiotensin modulators
    7. Antimigraine agents, other
    8. Antimigraine agents, triptans
    9. Bladder relaxant preparations
    10. H. pylori treatment
    11. Immunomodulators, atopic dermatitis
    12. Intranasal rhinitis agents
    13. Movement disorders
    14. Neuropathic pain
    15. Ophthalmics, anti-inflammatory/immunomodulator
    16. Phosphate binders
    17. Platelet aggregation inhibitors
    18. Progestins for cachexia
    19. Proton pump inhibitors
    20. Smoking cessation

Public comment on new drugs to be reviewed for the Medicaid PDL:

  1. Gastrointestinal (GI) motility, chronic / Symproic
  2. Glucocorticoids, inhaled / Armonair Respiclick
  3. Glucocorticoids, inhaled / Trelegy Ellipta
  4. Glucocorticoids, oral / Zodex
  5. HAE treatments / Haegarda
  6. Hypoglycemics, insulin and related agents / Fiasp FlexTouch pen
  7. Hypoglycemics, insulin and related agents / Fiasp vial
  8. Hypoglycemics, insulin and related agents / Humalog Junior KwikPen
  9. Stimulants and related agents / Cotempla XR-ODT
  10. Executive work session
    Pursuant to Texas Government Code, Section 531.071, and in accordance with Texas Administrative Code, Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DUR Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
  11. Lunch
  12. Announcements of drugs recommended for the Medicaid PDL
  13. Retrospective DUR:  Larry Dent, Pharm. D., BCPS, Conduent, LLC
    1. Report on recent retrospective DUR intervention sent for high dose attention deficit hyperactivity disorder medication management in youth
    2. Report on recent retrospective DUR intervention outcomes for GI management
    3. Retrospective DUR proposals:  (Vote required)
      1. Hypertension management
      2. Major depressive disorder management
      3. Benzodiazepine anxiolytics and controlled sedative hypnotics
  14. Prospective prior authorization proposals (clinical edits):  Christina Faulkner, Pharm. D., Health Information Designs, LLC (Vote required)
    1. Proton pump inhibitors
    2. Topical retinoids
  15. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (Vote required)
    1. Fentanyl (inhalation/oral/transdermal)
    2. Gabapentin
    3. Hydrocodone Bitartrate/Hydrocodone Polistirex
    4. Ivacaftor (Kalydeco®) and Lumacaftor/Ivacaftor (Orkambi®)
    5. Calcineurin Inhibitors - Pimecrolimus (Elidel®), Tacrolimus (Protopic®)
    6. Tramadol (Ultram®)
  16. Adjourn
  17. Next meeting date: April 27, 2018

Contact:  Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O. Castoreno, DUR/PDL Oversight Specialist, Health and Human Services Commission, Medicaid and CHIP Services Department, at 512-707-6112 or Maribel.Castoreno@hhsc.state.tx.us.

Information regarding submission of written comments and application to provide public testimony before the committee can be found at: https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-meetings.

This meeting is open to the public.  No reservations are required, and there is no cost to attend this meeting.

People with disabilities who wish to attend the meeting and require auxiliary aids or services should contact Castoreno at 512-707-6112 at least 72 hours before the meeting so appropriate arrangements can be made.